VGTI Florida® currently receives approximately 25% of its total funding from corporate sponsored research. Due to our scientific expertise in infectious diseases and cancer and state-of-the-art facilities and equipment, the Institute is pursued by biotech and biomedical commercial entities to collaborate on achieving mutually beneficial research and development goals.
Because our research relates to solving existing and emerging health issues, we are much more translational than research institutes and universities performing early-stage and basic research. We welcome the opportunity to work with start-ups, mid-sized biotechs, and big pharmaceutical companies on vaccines and immunotherapies for infectious diseases and cancer.
We welcome inquiries from commercial entities to discuss your research goals and how VGTI Florida could collaborate to achieve the goals of “Translating Research Into Health®.”